Search

A multivariate risk score model was proposed by Sieira et al in 2017 for sudden death in Brugada syndrome; their validation in 150 patients was highly encouraging, with a C-index of 0.81; however, this score is yet to be validated by an independent group. A total of 192 records of patients with Brugada syndrome were collected from 2 centers in the United Kingdom and retrospectively scored according to a score model by Sieira et al. Data were compiled summatively over follow-up to mimic regular risk re-evaluation as per current guidelines. Sudden cardiac death survivor data were considered perievent to ascertain the utility of the score before cardiac arrest. Scores were compared with actual outcomes. Sensitivity in our cohort was 22.7%, specificity was 57.6%, and C-index was 0.58. In conclusion, up to 75% of cardiac arrest survivors in this cohort would not have been offered a defibrillator if evaluated before their event. This casts doubt on the utility of the score model for primary prevention of sudden death. Inherent issues with modern risk scoring strategies decrease the likelihood of success even in robustly designed tools such as the Sieira score model.

Introduction: Strategies for reliable selection of high-risk hypertrophic cardiomyopathy (HCM) patients for prevention of sudden cardiac death (SCD) with implantable cardioverter-defibrillators (ICDs) continue to be debated. Objective: Assess the sensitivity of sudden death risk strategies in predicting SCD events (appropriate ICD shocks, sudden death or out of hospital cardiac arrest) among a large multicenter cohort of high-risk HCM patients. Methods: Observational longitudinal study from 6-HCM centers in North America and Europe to determine outcomes in consecutive HCM patients considered high risk for sudden death based on an enhanced ACC/AHA (U.S./Canada) guidelines-based risk factor algorithm with primary prevention ICD placement. ESC risk score was retrospectively calculated in this cohort and compared to ACC/AHA risk factor method for predicting SCD events. Results: Of 1185 patients with primary prevention ICDs implanted based on ≥ 1 major risk marker, 162 (14%) experienced device therapy terminating VT/VF episodes at 49 ± 18 years of age and 4.6 ± 4.2 years after device implant. Within the 6 HCM centers, only 28 other patients not implanted with ICD died suddenly or had resuscitated cardiac arrests, including 19 (68%) with risk-markers who declined ICDs. Of these 190 high risk patients with SCD or SCD events, 67 (35%) had ESC risk-scores scores ≥6%/5-years, considered sufficient to recommend a prophylactic ICD, while 83 (44%) had low risk scores ( Conclusion: In this large multicenter study of high-risk HCM patients, an enhanced ACC/AHA risk factor strategy was superior to the ESC risk score in identifying patients at greatest risk for SCD events.

Background Epicardial ganglionated plexuses (GP) have an important role in the pathogenesis of atrial fibrillation (AF). The relationship between anatomical, histological and functional effects of GP is not well known. We previously described atrioventricular (AV) dissociating GP (AVD-GP) locations. In this study, we hypothesised that ectopy triggering GP (ET-GP) are upstream triggers of atrial ectopy/AF and have different anatomical distribution to AVD-GP. Objectives We mapped and characterised ET-GP to understand their neural mechanism in AF and anatomical distribution in the left atrium (LA). Methods 26 patients with paroxysmal AF were recruited. All were paced in the LA with an ablation catheter. High frequency stimulation (HFS) was synchronised to each paced stimulus for delivery within the local atrial refractory period. HFS responses were tagged onto CARTO™ 3D LA geometry. All geometries were transformed onto one reference LA shell. A probability distribution atlas of ET-GP was created. This identified high/low ET-GP probability regions. Results 2302 sites were tested with HFS, identifying 579 (25%) ET-GP. 464 ET-GP were characterised, where 74 (16%) triggered ≥30s AF/AT. Median 97 (IQR 55) sites were tested, identifying 19 (20%) ET-GP per patient. >30% of ET-GP were in the roof, mid-anterior wall, around all PV ostia except in the right inferior PV (RIPV) in the posterior wall. Conclusion ET-GP can be identified by endocardial stimulation and their anatomical distribution, in contrast to AVD-GP, would be more likely to be affected by wide antral circumferential ablation. This may contribute to AF ablation outcomes., Highlights • ET-GP can be stimulated endocardially using high frequency stimulation within the local atrial refractory period. • ET-GP stimulation displays a wide range of responses from single ectopy to sustained AF and occasionally AV block. • ET-GP have distinct anatomical regions in patients with AF, and their distribution contrasts that of AV dissociating GP. • Most ET-GP are in the roof/PV ostia and inadvertently ablated during PVI. This may contribute to AF ablation success.

Introduction A spontaneous type I electrocardiogram (ECG) pattern and/or unheralded syncope are conventionally used as risk markers for primary prevention of sudden cardiac arrest/death (SCA/SCD) in Brugada syndrome (BrS). In this study, we determine the prevalence of conventional and newer markers of risk in those with and without previous aborted SCA events. Methods All patients with BrS were identified at our institute. History of symptoms was obtained from medical tests or from interviews. Other markers of risk were also obtained, such as presence of (1) spontaneous type I pattern, (2) fractionated QRS (fQRS), (3) early repolarization (ER) pattern, (4) late potentials on signal‐averaged ECG (SAECG), and (5) response to programmed electrical stimulation. Results In 133 patients with Bars, 10 (7%) patients (mean age = 39 ± 11 years; nine males) were identified with a previous ventricular fibrillation/ventricular tachycardia episode (n = 8) or requiring cardio‐pulmonary resuscitation (n = 2). None of these patients had a prior history of syncope before their SCA event. Only two (20%) patients reported a history of palpitations or dizziness. None had apneic breathing and three (30%) patients had a family history of SCA. From their ECGs, a spontaneous pattern was only found in one (10%) of these patients. Further, 10% of patients had fQRS, 17% had late potentials on SAECG, 20% had deep S waves in lead I, and 10% had an ER pattern in the peripheral leads. No significant differences were observed in the non‐SCA group. Conclusion The majority of BrS patients with previous aborted SCA events did not have a spontaneous type I and/or prior history of syncope. Conventional and newer markers of risk appear to only have limited ability to predict SCA.

Background: Models of cardiac arrhythmogenesis predict that non-uniformity in repolarization and/or depolarization promotes ventricular fibrillation and is modulated by autonomic tone, but this is difficult to evaluate in patients. We hypothesize that such spatial heterogeneities would be detected by non-invasive ECG imaging (ECGi) in sudden cardiac death (SCD) survivors with structurally normal hearts under physiological stress. Methods: ECGi was applied to 11 SCD survivors, 10 low-risk Brugada Syndrome patients (BrS) and 10 controls undergoing exercise treadmill testing. ECGi provides whole heart activation maps and > 1200 unipolar electrograms over the ventricular surface from which global dispersion of activation recovery interval (ARI) and regional delay in conduction were determined. These were used as surrogates for spatial heterogeneities in repolarization and depolarization. Surface ECG markers of dispersion (QT and Tpeak-end intervals) were also calculated for all patients for comparison. Results: Following exertion, the SCD group demonstrated the largest increase in ARI dispersion compared to BrS and control groups (13±8 ms vs 4±7 ms vs 4±5 ms; p = 0.009), with baseline dispersion being similar in all groups. In comparison, surface ECG markers of dispersion of repolarisation were unable to discriminate between the groups at baseline or following exertion. Spatial heterogeneities in conduction were also present following exercise but were not significantly different between SCD survivors and the other groups. Conclusion: Increased dispersion of repolarization is apparent during physiological stress in SCD survivors and is detectable with ECGi but not with standard ECG parameters. The electrophysiological substrate revealed by ECGi could be the basis of alternative risk-stratification techniques. This article is protected by copyright. All rights reserved

Aims Rate adaptation of the action potential ensures spatial heterogeneities in conduction across the myocardium are minimized at different heart rates providing a protective mechanism against ventricular fibrillation (VF) and sudden cardiac death (SCD), which can be quantified by the ventricular conduction stability (V-CoS) test previously described. We tested the hypothesis that patients with a history of aborted SCD due to an underlying channelopathy or cardiomyopathy have a reduced capacity to maintain uniform activation following exercise. Methods and results Sixty individuals, with (n = 28) and without (n = 32) previous aborted-SCD event underwent electro-cardiographic imaging recordings following exercise treadmill test. These included 25 Brugada syndrome, 13 hypertrophic cardiomyopathy, 12 idiopathic VF, and 10 healthy controls. Data were inputted into the V-CoS programme to calculate a V-CoS score that indicate the percentage of ventricle that showed no significant change in ventricular activation, with a lower score indicating the development of greater conduction heterogeneity. The SCD group, compared to those without, had a lower median (interquartile range) V-CoS score at peak exertion [92.8% (89.8–96.3%) vs. 97.3% (94.9–99.1%); P Conclusion Data from this pilot study demonstrate the potential use of this technique in risk stratification for the inherited cardiac conditions.

Typical atrial flutter is one of the most common of the atrial tachyarrhythmias and highly amenable to catheter ablation. This is based on a clear understanding of its electroanatomical circuit and critical dependence upon the cavo-tricuspid isthmus. Achieving a line of block across this isthmus is associated with a low rate of recurrence, reduced morbidity and improved quality of life.

Aims Abnormal rate adaptation of the action potential is proarrhythmic but is difficult to measure with current electro-anatomical mapping techniques. We developed a method to rapidly quantify spatial discordance in whole heart activation in response to rate cycle length changes. We test the hypothesis that patients with underlying channelopathies or history of aborted sudden cardiac death (SCD) have a reduced capacity to maintain uniform activation following exercise. Methods and results Electrocardiographical imaging (ECGI) reconstructs >1200 electrograms (EGMs) over the ventricles from a single beat, providing epicardial whole heart activation maps. Thirty-one individuals [11 SCD survivors; 10 Brugada syndrome (BrS) without SCD; and 10 controls] with structurally normal hearts underwent ECGI vest recordings following exercise treadmill. For each patient, we calculated the relative change in EGM local activation times (LATs) between a baseline and post-exertion phase using custom written software. A ventricular conduction stability (V-CoS) score calculated to indicate the percentage of ventricle that showed no significant change in relative LAT ( Conclusion We present a method to rapidly quantify changes in global activation which provides a measure of conduction heterogeneity and proof of concept by demonstrating SCD survivors have a reduced capacity to maintain uniform activation following exercise.

ObjectiveIn 2014, the European Society of Cardiology (ESC) recommended the use of a novel risk prediction model (HCM Risk-SCD) to guide use of implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We sought to determine the performance of HCM Risk-SCD by conducting a systematic review and meta-analysis of articles reporting on the prevalence of SCD within 5 years of evaluation in low, intermediate and high-risk patients as defined by the 2014 guidelines (predicted risk MethodsThe protocol was registered with PROSPERO (registration number: CRD42017064203). MEDLINE and manual searches for papers published from October 2014 to December 2017 were performed. Longitudinal, observational cohorts of unselected adult patients, without history of cardiac arrest were considered. The original HCM Risk-SCD development study was included a priori. Data were pooled using a random effects model.ResultsSix (0.9%) out of 653 independent publications identified by the initial search were included. The calculated 5-year risk of SCD was reported in 7291 individuals (70% low, 15% intermediate; 15% high risk) with 184 (2.5%) SCD endpoints within 5 years of baseline evaluation. Most SCD endpoints (68%) occurred in patients with an estimated 5-year risk of ≥4% who formed 30% of the total study cohort. Using the random effects method, the pooled prevalence of SCD endpoints was 1.01% (95% CI 0.52 to 1.61) in low-risk patients, 2.43% (95% CI 1.23 to 3.92) in intermediate and 8.4% (95% CI 6.68 to 10.25) in high-risk patients.ConclusionsThis meta-analysis demonstrates that HCM Risk-SCD provides accurate risk estimations that can be used to guide ICD therapy in accordance with the 2014 ESC guidelines.Registration numberPROSPERO CRD42017064203;Pre-results.

Background: The substrate location and underlying electrophysiological mechanisms that contribute to the characteristic ECG pattern of Brugada syndrome (BrS) are still debated. Using noninvasive electrocardiographical imaging, we studied whole heart conduction and repolarization patterns during ajmaline challenge in BrS individuals. Methods and Results: A total of 13 participants (mean age, 44±12 years; 8 men), 11 concealed patients with type I BrS and 2 healthy controls, underwent an ajmaline infusion with electrocardiographical imaging and ECG recordings. Electrocardiographical imaging activation recovery intervals and activation timings across the right ventricle (RV) body, outflow tract (RVOT), and left ventricle were calculated and analyzed at baseline and when type I BrS pattern manifested after ajmaline infusion. Peak J-ST point elevation was calculated from the surface ECG and compared with the electrocardiographical imaging–derived parameters at the same time point. After ajmaline infusion, the RVOT had the greatest increase in conduction delay (5.4±2.8 versus 2.0±2.8 versus 1.1±1.6 ms; P =0.007) and activation recovery intervals prolongation (69±32 versus 39±29 versus 21±12 ms; P =0.0005) compared with RV or left ventricle. In controls, there was minimal change in J-ST point elevation, conduction delay, or activation recovery intervals at all sites with ajmaline. In patients with BrS, conduction delay in RVOT, but not RV or left ventricle, correlated to the degree of J-ST point elevation (Pearson R , 0.81; P Conclusions: Magnitude of ST (J point) elevation in the type I BrS pattern is attributed to degree of conduction delay in the RVOT and not prolongation in repolarization time.

Background— The activation pattern of localized reentry (LR) in atrial tachycardia remains incompletely understood. We used the ultra–high density Rhythmia mapping system to study activation patterns in LR. Methods and Results— LR was suggested by small rotatory activations (carousels) containing the full spectrum of the color-coded map. Twenty-three left-sided atrial tachycardias were mapped in 15 patients (age: 64±11 years). 16 253±9192 points were displayed per map, collected over 26±14 minutes. A total of 50 carousels were identified (median 2; quartiles 1–3 per map), although this represented LR in only n=7 out of 50 (14%): here, rotation occurred around a small area of scar ( Conclusions— The activation pattern of LR is of small stable rotational activations (carousels), and this drove 30% (7/23) of our postablation atrial tachycardias. However, this appearance is most often pseudo-reentrant and must be differentiated by interpretation of electrograms in the candidate circuit and activation in the wider surrounding region.

Inclusion body myositis (IBM) is a late-onset inflammatory muscle disease (myopathy) associated with progressive proximal and distal limb muscle atrophy and weakness. Treatment options have attempted to target inflammatory and atrophic features of this condition (for example with immunosuppressive and immunomodulating drugs, anabolic steroids, and antioxidant treatments), although as yet there is no known effective treatment for reversing or minimising the progression of inclusion body myositis. In this review we have considered the benefits, adverse effects, and costs of treatment in targeting cardinal effects of the condition, namely muscle atrophy, weakness, and functional impairment.To assess the effects of treatment for IBM.On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register for Controlled Trials (CENTRAL), MEDLINE, and EMBASE. Additionally in November 2014 we searched clinical trials registries for ongoing or completed but unpublished trials.We considered randomised or quasi-randomised trials, including cross-over trials, of treatment for IBM in adults compared to placebo or any other treatment for inclusion in the review. We specifically excluded people with familial IBM and hereditary inclusion body myopathy, but we included people who had connective tissue and autoimmune diseases associated with IBM, which may or may not be identified in trials. We did not include studies of exercise therapy or dysphagia management, which are topics of other Cochrane systematic reviews.We used standard Cochrane methodological procedures.The review included 10 trials (249 participants) using different treatment regimens. Seven of the 10 trials assessed single agents, and 3 assessed combined agents. Many of the studies did not present adequate data for the reporting of the primary outcome of the review, which was the percentage change in muscle strength score at six months. Pooled data from two trials of interferon beta-1a (n = 58) identified no important difference in normalised manual muscle strength sum scores from baseline to six months (mean difference (MD) -0.06, 95% CI -0.15 to 0.03) between IFN beta-1a and placebo (moderate-quality evidence). A single trial of methotrexate (MTX) (n = 44) provided moderate-quality evidence that MTX did not arrest or slow disease progression, based on reported percentage change in manual muscle strength sum scores at 12 months. None of the fully published trials were adequately powered to detect a treatment effect. We assessed six of the nine fully published trials as providing very low-quality evidence in relation to the primary outcome measure. Three trials (n = 78) compared intravenous immunoglobulin (combined in one trial with prednisone) to a placebo, but we were unable to perform meta-analysis because of variations in study analysis and presentation of trial data, with no access to the primary data for re-analysis. Other comparisons were also reported in single trials. An open trial of anti-T lymphocyte immunoglobulin (ATG) combined with MTX versus MTX provided very low-quality evidence in favour of the combined therapy, based on percentage change in quantitative muscle strength sum scores at 12 months (MD 12.50%, 95% CI 2.43 to 22.57). Data from trials of oxandrolone versus placebo, azathioprine (AZA) combined with MTX versus MTX, and arimoclomol versus placebo did not allow us to report either normalised or percentage change in muscle strength sum scores. A complete analysis of the effects of arimoclomol is pending data publication. Studies of simvastatin and bimagrumab (BYM338) are ongoing. All analysed trials reported adverse events. Only 1 of the 10 trials interpreted these for statistical significance. None of the trials included prespecified criteria for significant adverse events.Trials of interferon beta-1a and MTX provided moderate-quality evidence of having no effect on the progression of IBM. Overall trial design limitations including risk of bias, low numbers of participants, and short duration make it difficult to say whether or not any of the drug treatments included in this review were effective. An open trial of ATG combined with MTX versus MTX provided very low-quality evidence in favour of the combined therapy based on the percentage change data given. We were unable to draw conclusions from trials of IVIg, oxandrolone, and AZA plus MTX versus MTX. We need more randomised controlled trials that are larger, of longer duration, and that use fully validated, standardised, and responsive outcome measures.La miositis por cuerpos de inclusión (MCI) es una enfermedad muscular inflamatoria (miopatía) de aparición tardía asociada con atrofia muscular y debilidad progresivas de los miembros proximales y distales. Las opciones de tratamiento se han intentado dirigir a las características inflamatorias y atróficas de esta afección (por ejemplo, con fármacos inmunosupresores e inmunomoduladores, esteroides anabólicos y tratamientos antioxidantes), aunque hasta ahora no hay un tratamiento eficaz conocido para la reversión o la reducción de la progresión de la miositis por cuerpos de inclusión. En esta revisión se han considerado los efectos beneficiosos, los efectos adversos y los costos del tratamiento dirigido a los efectos fundamentales de la afección, a saber, la atrofia muscular, la debilidad y el deterioro funcional.Evaluar los efectos del tratamiento para la MCI. MÉTODOS DE BÚSQUEDA: El 7 octubre 2014, se hicieron búsquedas en el registro especializado del Grupo Cochrane de Enfermedades Neuromusculares (Cochrane Neuromuscular Disease Group), en el Registro Cochrane Central de Ensayos Controlados (Cochrane Central Register of Controlled Trials) (CENTRAL), MEDLINE y en EMBASE. Además, en noviembre 2014 se realizaron búsquedas de ensayos en curso o terminadas pero no publicados en los registros de ensayos clínicos. CRITERIOS DE SELECCIÓN: Se consideraron para inclusión en la revisión los ensayos aleatorios o cuasialeatorios, incluidos los ensayos cruzados (crossover), del tratamiento para la MCI en adultos en comparación con placebo u otro tratamiento. Se excluyeron específicamente los pacientes con MCI familiar y miopatía por cuerpos de inclusión hereditaria, pero se incluyeron los pacientes con enfermedades del tejido conjuntivo y autoinmunitarias asociadas con MCI, que pueden o no identificarse en los ensayos. No se incluyeron los estudios de terapia con ejercicios o tratamiento de la disfagia, que son los temas de otras revisiones sistemáticas Cochrane. OBTENCIÓN Y ANÁLISIS DE LOS DATOS: Se utilizaron procedimientos metodológicos Cochrane estándar.La revisión incluyó diez ensayos (249 participantes) que utilizaron diferentes regímenes de tratamiento. Siete de los diez ensayos evaluaron agentes únicos y tres evaluaron agentes combinados. Muchos de los estudios no presentaron datos suficientes para el informe del resultado primario de la revisión, que fue el cambio porcentual en la puntuación de fuerza muscular a los seis meses. Los datos agrupados de dos ensayos de interferón beta‐1a (n = 58) no identificaron diferencias importantes en las puntuaciones normalizadas de la suma de la fuerza muscular manual desde el inicio hasta los seis meses (diferencia de medias [DM] ‐0,06; IC del 95%: ‐0,15 a 0,03) entre IFN beta‐1a y placebo (pruebas de calidad moderada). Un único ensayo de metotrexato (MTX) (n = 44) proporcionó pruebas de calidad moderada de que el MTX no detuvo ni enlenteció la progresión de la enfermedad, sobre la base del cambio porcentual informado en las puntuaciones de la suma de la fuerza muscular manual a los 12 meses. Ninguno de los ensayos publicados completamente tuvo poder estadístico suficiente para detectar un efecto del tratamiento. Se consideró que seis de los nueve ensayos publicados completamente aportaron pruebas de calidad muy baja con respecto a la medida de resultado primaria. Tres ensayos (n = 78) compararon la inmunoglobulina intravenosa (combinada en un ensayo con prednisona) con placebo, pero no fue posible realizar el metanálisis debido a las variaciones en el análisis de los estudios y a la presentación de los datos del ensayo, sin acceso a los datos primarios para el reanálisis. Otras comparaciones también se informaron en ensayos individuales. Un ensayo abierto de inmunoglobulina anti‐linfocitos T (IgAT) combinada con MTX versus MTX proporcionó pruebas de calidad muy baja a favor del tratamiento combinado, sobre la base del cambio porcentual en las puntuaciones cuantitativas de la suma de la fuerza muscular a los 12 meses (DM 12,50%; IC del 95%: 2,43 a 22,57). Los datos de los ensayos de oxandrolona versus placebo, azatioprina (AZA) combinada con MTX versus MTX y arimoclomol versus placebo no permitieron informar sobre el cambio porcentual o normalizado en las puntuaciones de la suma de la fuerza muscular. Un análisis completo de los efectos del arimoclomol está pendiente de la publicación de los datos. Están en curso estudios de simvastatina y bimagrumab (BYM338). Todos los ensayos analizados informaron eventos adversos. Solamente uno de los diez ensayos interpretó la significación estadística de los eventos adversos. Ninguno de los ensayos incluyó criterios preespecificados para los eventos adversos significativos.Los ensayos de interferón beta‐1a y MTX proporcionaron pruebas de calidad moderada de que no tienen efectos sobre la progresión de la MCI. Las limitaciones generales del diseño de los ensayos, que incluyen el riesgo de sesgo, los escasos números de participantes y la corta duración, hacen difícil determinar si alguno de los tratamientos farmacológicos incluidos en esta revisión fue eficaz. Un ensayo abierto de ATG combinada con MTX versus MTX aportó pruebas de calidad muy baja a favor del tratamiento combinado sobre la base de los datos de cambio porcentual facilitados. No fue posible establecer conclusiones de los ensayos de IgIV, oxandrolona y AZA más MTX versus MTX. Se necesitan más ensayos controlados aleatorios de mayor tamaño, con una duración más prolongada y que utilicen medidas de resultado completamente validadas, estandarizadas y de interés.

Introduction In Brugada Syndrome (BrS), the substrate location and underlying electrophysiological mechanisms that contribute to the characteristic ECG pattern are still debated. Using non-invasive electrocardiographical imaging (ECGi), we study whole heart conduction and repolarisation patterns following an ajmaline challenge in individuals with concealed Type I BrS. Methods 13 participants (mean age 44 ± 12 yrs; 8 males), 11 concealed Type I BrS and 2 controls, underwent an Ajmaline infusion with ECGI and ECG recordings for a research study. ECGi technology reconstructs >1000 electrograms (EGMs) from 252 surface electrode vest and projects this mathematically onto a 3D cardiac image created using a CT scan. Activation time points were determined as the QRS (dP/dtmin) and repolarisation time as (dP/dtmax) for positive T waves and (dp/dtmin) for negative or biphasic T waves, annotated using a custom built semi-automated software off-line. From these data, the local activation recovery interval (ARI), a surrogate of action potential duration, and activation timings across the right ventricle (RV) body, out flow tract (RVOT), and left ventricle (LV) were computed for all participants (Figure 1a). Changes in AT timings and ARI across the RVOT, RV and LV with ajmaline were calculated, and correlated with peak ST elevation (STE) derived from the ECG at the same time point. Results Following ajmaline administration, the greatest median increase in conduction delay was noted in the RVOT than in the RV or LV (5[3–8] ms vs 1[0–4]ms vs 1[0–2] ms; p Conclusion Magnitude of STE in the Type I BrS pattern is attributed to degree of conduction delay in the RVOT and not prolongation in repolarisation time.

A previously fit and well 28-year-old man was referred by his general practitioner to a nearby NHS walk-in centre for an ECG. He presented with a 1-day history of mild pleuritic chest discomfort and dyspnoea while at work. Simple analgesics alleviated the discomfort and improved the dyspnoea slightly. He had a BP of 121/78, a HR of 66 bpm and had an oxygen saturation of 98%. The ECG was electronically sent to a cardiologist based at …

Introduction Implantable cardio-defibrillators (ICDs) have proven benefit in treating lethal ventricular arrhythmias and preventing sudden death (SD) in hypertrophic cardiomyopathy (HCM), making risk stratification essential. We retrospectively evaluate the effectiveness of the 2014 European Society of Cardiology (ESC) risk scoring system in our cohort of HCM patients. Methods We evaluated the ESC risk scoring system which employs mathematical and statistical modelling of 7 disease variables to predict SD risk over 5 years, with a recommendation for ICD implant if SD risk ≥6%. From our cohort of HCM patients previously evaluated at our centre, we retrospectively calculated the ESC 5 year SD risk score at point of implant and measured it against ICD outcome. Decision of ICD implant, prior to the introduction of the ESC scoring system, was based on clinical history and number of conventional risk markers as defined by the American College of Cardiology and Heart Association. Results 52 out of 199 HCM patients (mean age 51 ± 13 yrs) underwent ICD implantation for primary prevention, with 8 (15%) having appropriate therapy for sustained ventricular tachycardia/fibrillation (VT/VF) over an average follow up period of 6.2 ± 4.9 yrs. There was no difference in the ESC risk scores between patients with or without device therapy (4.79% ± 1.5 vs 5.37% ± 3.3, p = 0.68) (Table 1). 5 of 8 (62%) patients with appropriate therapies for VT/VF had scores ranging from 3.08–5.05% and would not have reached the threshold for an ICD recommendation. In two an ICD would not be recommended and may be considered in the other three. Conclusion The current ESC scoring system potentially leaves many high-risk patients unprotected or with ambiguous ICD implant guidance. Lowering the current threshold may improve accuracy.

Introduction Sudden death in Brugada Syndrome (BrS) is associated with rest, when parasympathetic tone predominates and/or sympathetic tone is diminished. Non-invasive electrocardiographical imaging (ECGi) allows electrophysiological properties to be studied outside the cardiac catheter laboratory. We tested the hypothesis that in BrS the electrophysiological response to autonomic stimulation can be measured with ECGi. Methods Patients with ajmaline induced Type 1 Brugada ECG pattern and those with ventricular ectopy (as the control group) requiring electrophysiological studies were recruited. Anti-arrhythmic medications were stopped 5 days before the study, and echocardiography showed structurally normal hearts in all the participants. CT-chest was performed with an ECGi vest to analyse reconstructed epicardial electrograms (EGMs) on a 3D geometry of the patient’s heart. Activation recovery interval (ARI), an action potential duration surrogate, of the epicardial EGM was taken from right and left apical, mid and basal regions of the ventricle from each individual and corrected for heart rate (cARI) at rest and during the various autonomic states of peak exertion, recovery (with exercise treadmill test) and postural change (with tilt table testing). Results There were 4 patients in the BrS group (mean age 51 yrs; 4 males) and 4 patients in the control group (mean age 30; 2 males and 2 females). All patients were able to achieve their maximum target heart rate for age on treadmill, and all had completed the tilt table test with 1 in each group displaying evidence of orthostatic intolerance. Baseline cARI was not significantly different between groups (299 ± 17 msec vs 284 ± 18 msec; p=ns) (Table 1). There was appropriate shortening of cARI (299 ± 17 msec to 258 ± 22 msec; p = 0.006) from baseline to peak exertion, and prolongation on recovery (258 ± 22 msec to 296 ± 23 msec; p = 0.03) in the control group, but not in the BrS group. With upright tilt, a significant increase in cARI was noted in the control group by 5 and 20 min (p Conclusion This study shows how cARI during autonomic challenge is different for BrS patients. This could be the basis of an alternative approach to risk stratification.

A 36-year-old woman was referred to our neurological and cardiological services with recurrent blackouts. She was diagnosed at age 6 with nocturnal generalised tonic-clonic seizures, which settled by age 13 with Carbamazepine. During adulthood, her seizures were thought to have recurred, but now occurred upon rising up from bed and were preceded by palpitations, breathlessness and light-headedness. Having passed out, she would often bite her cheek, lose urinary continence and was seen to convulse. Upon termination, she would recover rapidly without a clear postictal phase. Our patient's grandmother died suddenly of an unknown cause at age 44. Neurological investigations showed a …